TOMASZ BEER

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. pmc Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men
    Christine M Barnett
    Division of Hematology and Medical Oncology and the Knight Cancer Institute, Oregon Health and Science University, CH 14R, 3303 SW Bond Ave, Portland, OR 97239, USA
    Cancer Causes Control 21:1297-303. 2010
  2. doi request reprint Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Urology 82:410-5. 2013
  3. pmc Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    T M Beer
    Knight Cancer Institute, Oregon Health and Science University, Mail code CH14R, 3303 SW Bond Avenue, Portland, OR 97239, USA
    Br J Cancer 107:808-13. 2012
  4. doi request reprint A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    Tomasz M Beer
    Knight Cancer Institute, Oregon Health and Science University, 3303 SW Bond Ave, Portland, OR 97239, USA
    Anticancer Drugs 21:433-8. 2010
  5. ncbi request reprint Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer 106:2624-9. 2006
  6. ncbi request reprint Effect of calcitriol on prostate-specific antigen in vitro and in humans
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 12:2812-6. 2006
  7. ncbi request reprint Testosterone loss and estradiol administration modify memory in men
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    J Urol 175:130-5. 2006
  8. ncbi request reprint Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, 97239, USA
    Clin Cancer Res 11:7794-9. 2005
  9. ncbi request reprint ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland 97239, USA
    BJU Int 96:508-13. 2005
  10. ncbi request reprint Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    J Clin Oncol 25:669-74. 2007

Collaborators

Detail Information

Publications81

  1. pmc Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men
    Christine M Barnett
    Division of Hematology and Medical Oncology and the Knight Cancer Institute, Oregon Health and Science University, CH 14R, 3303 SW Bond Ave, Portland, OR 97239, USA
    Cancer Causes Control 21:1297-303. 2010
    ..We sought to examine the association between vitamin D and prostate cancer risk in a cohort of older men...
  2. doi request reprint Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Urology 82:410-5. 2013
    ....
  3. pmc Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    T M Beer
    Knight Cancer Institute, Oregon Health and Science University, Mail code CH14R, 3303 SW Bond Avenue, Portland, OR 97239, USA
    Br J Cancer 107:808-13. 2012
    ..This is the first study to investigate the activity and safety of sagopilone in patients with metastatic castration-resistant PC (CRPC)...
  4. doi request reprint A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    Tomasz M Beer
    Knight Cancer Institute, Oregon Health and Science University, 3303 SW Bond Ave, Portland, OR 97239, USA
    Anticancer Drugs 21:433-8. 2010
    ..The median time to progression was 4 weeks. In conclusion, this regimen of low-dose transdermal estradiol induction followed by PPX does not have activity in taxane pretreated patients with castration-resistant prostate cancer...
  5. ncbi request reprint Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer 106:2624-9. 2006
    ..To the authors' knowledge, no satisfactory therapy is available for patients with refractory germ cell neoplasms. The activity and safety of arsenic trioxide in refractory germ cell tumors was assessed...
  6. ncbi request reprint Effect of calcitriol on prostate-specific antigen in vitro and in humans
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 12:2812-6. 2006
    ..We examined the effects of calcitriol at similar concentration on cell proliferation, androgen receptor (AR) expression, and PSA production in vitro and on PSA concentrations in prostate cancer patients...
  7. ncbi request reprint Testosterone loss and estradiol administration modify memory in men
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    J Urol 175:130-5. 2006
    ..We characterized the impact of androgen deprivation and of subsequent estradiol therapy on the long-term and working memory of patients with prostate cancer...
  8. ncbi request reprint Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, 97239, USA
    Clin Cancer Res 11:7794-9. 2005
    ..In this dose escalation study, we sought to evaluate the tolerability and pharmacokinetics of a single oral dose of DN-101, a high-dose calcitriol formulation...
  9. ncbi request reprint ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland 97239, USA
    BJU Int 96:508-13. 2005
    ..The ASCENT design and its strengths and limitations are presented...
  10. ncbi request reprint Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    J Clin Oncol 25:669-74. 2007
    ..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel...
  11. ncbi request reprint Rationale for the development and current status of calcitriol in androgen-independent prostate cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Mail Code CR 145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    World J Urol 23:28-32. 2005
    ..An international placebo-controlled randomized trial that is currently under way will provide more robust information about the safety and efficacy of this combination...
  12. ncbi request reprint Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, CR 145, Portland, OR 97239, USA
    Cancer Epidemiol Biomarkers Prev 13:2225-32. 2004
    ..In this study, we selected this approach to test several hypotheses about the effect of calcitriol (1,25-dihydroxycholecalciferol), the active form of vitamin D, on early-stage human prostate cancer...
  13. ncbi request reprint Calcitriol in the treatment of prostate cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, 97239, USA
    Anticancer Res 26:2647-51. 2006
    ..DN-101 in combination with docetaxel is being evaluated in a placebo-controlled randomized clinical trial that has completed accrual...
  14. ncbi request reprint High dose calcitriol may reduce thrombosis in cancer patients
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Br J Haematol 135:392-4. 2006
    ..In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans...
  15. ncbi request reprint Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study
    Tomasz M Beer
    Division of Hematology and Medical Oncology and OHSU Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Anticancer Drugs 17:1075-9. 2006
    ....
  16. doi request reprint Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer
    Tomasz M Beer
    Oregon Health and Science University Knight Cancer Institute, Portland, Oregon, USA
    Clin Cancer Res 17:4558-67. 2011
    ..Sipuleucel-T, an autologous cellular immunotherapy, was investigated in a randomized, double-blind, controlled trial to determine its biologic activity in androgen-dependent prostate cancer (ADPC)...
  17. pmc Acupuncture for hot flashes in patients with prostate cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Urology 76:1182-8. 2010
    ..Hot flashes are a common adverse effect of hormonal therapy for prostate cancer...
  18. doi request reprint Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes
    Tomasz M Beer
    Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Clin Genitourin Cancer 6:103-9. 2008
    ..In this study, we sought to assess the efficacy of ispinesib, a mitotic kinesin spindle protein (KSP) inhibitor in androgen-independent prostate cancer progressing after docetaxel...
  19. ncbi request reprint Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy
    Tomasz M Beer
    Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Clin Genitourin Cancer 6:36-9. 2008
    ..The purpose of this study was to characterize the activity and toxicity of irinotecan in metastatic platinum-refractory urothelial carcinoma...
  20. doi request reprint C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, OR 97239, USA
    Cancer 112:2377-83. 2008
    ..The authors sought to determine whether specific blood proteins associated with inflammation predict for outcomes in men with metastatic androgen-independent prostate cancer (AIPC) who are initiating docetaxel-based chemotherapy...
  21. ncbi request reprint Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer 112:326-30. 2008
    ..In the current study, the authors examined retreatment with the same regimen after a treatment holiday...
  22. ncbi request reprint Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Clin Genitourin Cancer 5:329-33. 2007
    ..We sought to determine if infrequent dosing of darbepoetin alfa is safe and effective in treating anemia in patients receiving systemic therapy for prostate cancer...
  23. ncbi request reprint Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel
    Tomasz M Beer
    Department of Medicine, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Invest New Drugs 25:565-70. 2007
    ..6%). One subject (2.6%) had a grade 4 treatment peripheral motor neuropathy. Further study of this dose and schedule of KOS-862 in this patient population cannot be recommended due to both lack of activity and excessive toxicity...
  24. ncbi request reprint Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code CR 145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Cancer Chemother Pharmacol 59:581-7. 2007
    ..DN-101 is a new, high-dose, oral formulation of calcitriol under investigation for the treatment of cancer. We sought to evaluate the tolerability and pharmacokinetics (PK) of weekly doses of DN-101 in patients with advanced cancer...
  25. ncbi request reprint High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer
    Tomasz M Beer
    Department of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA
    Am J Clin Oncol 27:535-41. 2004
    ..Despite encouraging preclinical evidence, the addition of oral calcitriol to carboplatin in this study was not associated with an increase in the response rate when compared with the reported activity of carboplatin alone...
  26. ncbi request reprint Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer
    Tomasz M Beer
    Divisions of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Clin Cancer Res 10:1306-11. 2004
    ..The purpose is to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of mitoxantrone and docetaxel administered weekly before prostatectomy in men with localized prostate cancer at high risk for recurrence...
  27. ncbi request reprint Calcitriol in cancer treatment: from the lab to the clinic
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA
    Mol Cancer Ther 3:373-81. 2004
    ..Further work is needed to elucidate the molecular mechanisms of antineoplastic activity and optimal clinical applications of calcitriol in cancer...
  28. ncbi request reprint Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer
    Tomasz M Beer
    Department of Medicine, Oregon Health and Science University, Mail Code L586, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
    Curr Urol Rep 3:232-8. 2002
    ..Larger randomized studies targeting patients with sufficient prevalence and intensity of pain are needed to refine our understanding of the contribution of docetaxel to pain control in this patient population...
  29. ncbi request reprint Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer
    Tomasz M Beer
    Oregon Health and Science University and Portland VA Medical Center, Portland, OR 97239, USA
    J Clin Oncol 21:123-8. 2003
    ....
  30. ncbi request reprint Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland 97239, Oregon, USA
    Cancer 100:758-63. 2004
    ..The current study evaluated the analgesic activity and impact on quality of life (QOL) of a new chemotherapy regimen of calcitriol and docetaxel in men with androgen-independent prostate carcinoma...
  31. ncbi request reprint High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland 97239 3098, USA
    Cancer 97:1217-24. 2003
    ..This study sought to define the long-term toxicity of this regimen and measure its effect on serum prostate specific antigen (PSA) levels in patients with hormone-naïve prostate carcinoma...
  32. ncbi request reprint Docetaxel (taxotere) in the treatment of prostate cancer
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Oncology, Oregon Health and Science University, Portland 97329, USA
    Expert Rev Anticancer Ther 3:261-8. 2003
    ..Similarly, a number of investigators are conducting exploratory trials that incorporate docetaxel into multimodality approaches to high-risk localized prostate cancer treatment...
  33. ncbi request reprint Development of weekly high-dose calcitriol based therapy for prostate cancer
    Tomasz M Beer
    Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Urol Oncol 21:399-405. 2003
    ..4 months and median survival of 19.5 months, compared favorably to results with docetaxel alone and led to the development of a recently initiated randomized trial of docetaxel with calcitriol or placebo in the same patient population...
  34. pmc Intermittent chemotherapy in metastatic androgen-independent prostate cancer
    T M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Mail Code L586, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Br J Cancer 89:968-70. 2003
    ..Chemotherapy holiday was associated with an improvement of fatigue (P=0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study...
  35. ncbi request reprint Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, CR 145, Portland, OR 97239, USA
    Clin Prostate Cancer 2:167-72. 2003
    ..These findings are consistent with the hypothesis that docetaxel chemotherapy in patients with AIPC is equally well tolerated and effective across a wide range of ages...
  36. ncbi request reprint Prevention and management of prostate cancer chemotherapy complications
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Mail Code CR145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Urol Clin North Am 31:367-78. 2004
    ..Successful palliation depends on reducing cancer-related suffering without introducing treatment-related suffering. Thus prevention and management of toxicity is central to the success of chemotherapy in advanced prostate cancer...
  37. ncbi request reprint A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation
    T M Beer
    Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland, Oregon 97201, USA
    Cancer 91:2431-9. 2001
    ....
  38. ncbi request reprint Polymorphisms of GSTP1 and related genes and prostate cancer risk
    T M Beer
    Division of Hematology and Medical Oncology, Oregon Health Sciences University, Oregon, USA
    Prostate Cancer Prostatic Dis 5:22-7. 2002
    ..This population fails to identify a relationship between the above polymorphisms and prostate adenocarcinoma...
  39. ncbi request reprint Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Urol 172:2213-7. 2004
    ....
  40. ncbi request reprint Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
    T M Beer
    Department of Medicine, Oregon Health Sciences University, Portland 97201, USA
    Ann Oncol 12:1273-9. 2001
    ..This study sought to define the activity and toxicity of weekly docetaxel in patients with androgen-independent prostate cancer and cancer-related pain...
  41. pmc Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer
    T M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Mail Code CR145, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Br J Cancer 91:1425-7. 2004
    ..Intermittent chemotherapy for AIPC is feasible and deserves further study...
  42. ncbi request reprint Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Urology 63:342-7. 2004
    ..To determine the efficacy of the gonadotropin-releasing hormone antagonist abarelix in patients with androgen-independent prostate cancer progressing after orchiectomy and to measure its effect on serum follicle-stimulating hormone (FSH)...
  43. pmc Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer
    Mark Garzotto
    Division of Urology, Oregon Health and Science University, Portland Veterans Administration Medical Center, Portland, Oregon, USA
    Cancer 116:1699-708. 2010
    ..Secondary endpoints included safety, pathologic effects of chemotherapy, and predictors of disease recurrence...
  44. ncbi request reprint High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study
    Natasha M Tiffany
    Division of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland 97239, USA
    J Urol 174:888-92. 2005
    ....
  45. ncbi request reprint Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer
    Daniel M Janoff
    Division of Urology, Oregon Health and Science University and Portland VA Medical Center, Oregon 97239, USA
    BJU Int 96:503-7. 2005
    ....
  46. ncbi request reprint Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer
    R Bruce Montgomery
    Department of Medicine, Veterans Affairs Puget Sound Health Care System VAPSHCS, and University of Washington School of Medicine, Seattle, WA 98108, USA
    Cancer 110:996-1002. 2007
    ..The addition of diethylstilbestrol to docetaxel modified tubulin composition and improved the response of prostate cancer to chemotherapy in preclinical models. An attempt was made to recapitulate the observations in a clinical trial...
  47. doi request reprint A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer
    Joseph S Chan
    Oregon Health and Science University, Portland, OR 97239, USA
    BJU Int 102:1601-6. 2008
    ..To evaluate the preliminary efficacy, safety, and impact on quality of life (QoL) of high-dose calcitriol (DN-101) combined with mitoxantrone and glucocorticoids in androgen-independent prostate cancer (AIPC)...
  48. pmc Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer
    Catherine O'Brien
    Oregon Health and Science University, Portland, 97239, USA
    Am J Clin Pathol 133:654-61. 2010
    ..In multivariable logistic regression analysis, only intraductal pattern (P = .007) predicted lymph node metastases. Intraductal and cribriform histologic features apparently predict postchemotherapy outcome...
  49. pmc CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity
    David Z Qian
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Prostate 70:433-42. 2010
    ..Metastatic prostate cancer is either inherently resistant to chemotherapy or rapidly acquires this phenotype after chemotherapy exposure. In this study, we identified a docetaxel-induced resistance mechanism centered on CCL2...
  50. doi request reprint Optimal timing of chemotherapy in androgen independent prostate cancer
    Ian D Schnadig
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Urol Oncol 27:97-100. 2009
    ..To interpret available docetaxel clinical trial data in order to define optimal timing of the initiation of chemotherapy in androgen independent prostate cancer (AIPC)...
  51. ncbi request reprint The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Cancer 107:489-96. 2006
    ....
  52. ncbi request reprint Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL
    Mark Garzotto
    Division of Urology, Portland Veterans Administration Medical Center, Portland, Oregon
    Cancer 98:1417-22. 2003
    ..The objective of the current study was to develop a model for predicting the presence of prostate carcinoma using clinical, laboratory, and transrectal ultrasound (TRUS) data...
  53. ncbi request reprint Unilateral autonomous testicular testosterone production mimicking androgen independent prostate cancer
    Michael Lavelle
    Division of Urology, Oregon Health and Science University, Portland, OR, USA
    J Urol 168:1098-9. 2002
  54. ncbi request reprint Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen
    Irene Panagiotou
    Division of Hematology and Medical Oncology, Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Oncology 67:194-202. 2004
    ..To identify risk factors for delayed cancer-directed intervention in modern era prostate cancer patients who initially elect expectant management...
  55. ncbi request reprint Successful treatment of metastatic hormone-refractory prostate cancer with malignant pericardial tamponade using docetaxel
    Brandon M Hayes-Lattin
    Oregon Health and Science University, Portland, Oregon 97201, USA
    Urology 59:137. 2002
    ..This case suggests that patients with pericardial tamponade due to hormone-refractory prostate cancer do not have a uniformly dismal prognosis and should be considered for aggressive treatment...
  56. ncbi request reprint Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study
    Julie N Graff
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Urol 177:1307-12. 2007
    ..We determined which demographic and clinical factors predict overall and cancer specific survival with this treatment strategy in patients enrolled in the Prostate Cancer Outcomes Study...
  57. ncbi request reprint Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy
    Tomasz M Beer
    Division of Hematology, Oregon Health and Science University, Portland, OR, USA
    J Urol 169:1738-41. 2003
    ..We determine the clinical efficacy of the gonadotropin-releasing hormone (Gn-RH) antagonist abarelix in patients with androgen independent prostate cancer, and measure its effect on serum follicle-stimulating hormone (FSH) and testosterone...
  58. pmc Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium
    Jonathan E Rosenberg
    Department of Medicine, University of California San Franscisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 27:2772-8. 2009
    ..Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castration-resistant prostate cancer (CRPC) patients. Clinical noncrossresistance was previously observed...
  59. ncbi request reprint Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer
    Jonathan Q Purnell
    Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, OR 97239, USA
    J Lipid Res 47:349-55. 2006
    ..Compared with ADT, short-term TDE therapy of prostate cancer improves lipid levels without deterioration of CVD-associated inflammatory markers and may, on longer-term follow-up, improve CVD and mortality rates...
  60. ncbi request reprint Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy
    Stephen E F Spurgeon
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Urology 69:931-5. 2007
    ..We hypothesized that the prebiopsy PSA doubling time (PSADT) and PSA velocity (PSAV) could predict for cancer detection in a referral population with a suspicion of prostate cancer...
  61. doi request reprint A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma
    Christopher W Ryan
    Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA
    Invest New Drugs 29:374-9. 2011
    ..The primary endpoint was estimation of the 3-month progression-free rate...
  62. ncbi request reprint Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies
    Mark Garzotto
    Urology Section, Portland Veterans Administration Medical Center, Portland, Oregon 97239, USA
    Cancer 104:1911-7. 2005
    ..The current study was performed to identify risk factors and risk groups for carcinoma detection in men undergoing repeat prostate biopsies...
  63. pmc ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21
    Hao Geng
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer Res 70:3239-48. 2010
    ..Taken together, it shows that ID1 expression has a novel therapeutic role in prostate cancer chemotherapy and prognosis...
  64. ncbi request reprint Fine-needle aspiration diagnosis of plasmacytoma presenting as breast masses in a patient on estrogen therapy for prostate cancer
    John T Vetto
    Division of Surgical Oncology, Department of Surgery, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Diagn Cytopathol 31:417-9. 2004
    ....
  65. ncbi request reprint Improved detection of prostate cancer using classification and regression tree analysis
    Mark Garzotto
    Urology Section, Division of Urology, Portland Veterans Administration Medical Center, 3710 SW US Veterans Hospital Rd, Portland, OR 97239, USA
    J Clin Oncol 23:4322-9. 2005
    ..To build a decision tree for patients suspected of having prostate cancer using classification and regression tree (CART) analysis...
  66. ncbi request reprint Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy
    Christine M Barnett
    Knight Cancer Institute, Oregon Health and Science University, Mail Code L586, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Anticancer Res 31:973-4. 2011
    ..We present the case of a patient with biochemically relapsed prostate cancer treated with early docetaxel after initial incomplete response to AST who now has a prolonged response to therapy...
  67. pmc Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 375:1437-46. 2010
    ..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease...
  68. pmc Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  69. ncbi request reprint Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?
    Jennifer L Lycette
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Clin Genitourin Cancer 5:198-205. 2006
    ....
  70. ncbi request reprint Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer
    Christopher W Ryan
    Division of Hematology Oncology, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA
    J Urol 176:972-8; discussion 978. 2006
    ..We evaluated the effect of zoledronic acid initiated subsequent to androgen deprivation therapy on bone mineral density and biochemical markers of bone turnover...
  71. ncbi request reprint Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy
    Christopher W Ryan
    Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Urology 70:122-6. 2007
    ..We sought to examine the impact of ADT and lifestyle variables on BMD in 120 patients with prostate cancer without bone metastases entering a randomized clinical trial...
  72. ncbi request reprint Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer
    Mark Garzotto
    Urology Section, Surgical Service, Portland VA Medical Center, Portland, OR 97239, USA
    Urol Oncol 24:254-9. 2006
    ..The goal of this phase I/II study is to evaluate the safety and efficacy of neoadjuvant docetaxel and mitoxantrone before prostatectomy...
  73. ncbi request reprint Views on physician-assisted suicide among family members of Oregon cancer patients
    Linda Ganzini
    Department of Psychiatry, Oregon Health and Science University, Portland VA Medical Center, 97207, USA
    J Pain Symptom Manage 32:230-6. 2006
    ..Improved knowledge of patient-based barriers to discussing PAS may facilitate interventions for psychosocial distress in cancer patients...
  74. ncbi request reprint Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
    Adam S Kibel
    Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri 63105, USA
    J Urol 177:1777-81. 2007
    ..Patients with adverse pathological features are at high risk for recurrence following radical prostatectomy. To improve outcomes in this population we performed a phase II study of adjuvant docetaxel in these high risk patients...
  75. ncbi request reprint Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer
    Randall P Rago
    H Lee Moffitt Cancer Center, Tampa, FL, USA
    Cancer Chemother Pharmacol 51:297-305. 2003
    ..Since mitoxantrone (M) and prednisone (P) are substrates for MDR transporters, we initiated a study to evaluate the safety, pharmacokinetics, and efficacy of VX-710 plus M/P in patients with hormone-refractory prostate cancer (HRPC)...
  76. ncbi request reprint A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
    Robert W Ross
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:521-6. 2008
    ..The authors conducted a phase 2 trial of docetaxel plus carboplatin chemotherapy in this disease setting...
  77. ncbi request reprint Polymorphisms of GSTT1 and related genes in head and neck cancer risk
    Adam J Evans
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Mail Code L586, Portland, Oregon 97201, USA
    Head Neck 26:63-70. 2004
    ..We sought to determine whether GSTT1 genotype and genotypes of several related genes are associated with risk of squamous cell carcinoma of the head and neck (HNSCC)...
  78. ncbi request reprint Statins and prostate cancer risk: a case-control study
    Jackilen Shannon
    Oregon Health and Sciences University, Portland, OR 97239 3098, USA
    Am J Epidemiol 162:318-25. 2005
    ..24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer...
  79. doi request reprint The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells
    Anne Myrthue
    Division of Hematology and Medical Oncology, Oregon Health and Science University, CH 14R, 3303 SW Bond Avenue, Portland, OR 97239, USA
    Clin Cancer Res 14:3562-70. 2008
    ..Irx5 may be a promising new therapeutic target in cancer treatment...
  80. ncbi request reprint Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature
    Jennifer L Lycette
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Mailcode L586, Portland, OR 97239, USA
    Breast Cancer Res Treat 99:249-55. 2006
    ....
  81. ncbi request reprint Interest in physician-assisted suicide among Oregon cancer patients
    Linda Ganzini
    Oregon Health and Science University OHSU, Interprofessional Palliative Care Fellowship at the Portland VA Medical Center in Portland, Oregon, USA
    J Clin Ethics 17:27-38. 2006

Research Grants7

  1. Oregon Prostate Cancer Conference 2001
    TOMASZ BEER; Fiscal Year: 2003
    ....
  2. Acupuncture for hot flashes in prostate cancer patients
    TOMASZ BEER; Fiscal Year: 2004
    ..The overall goal is to provide prostate cancer patients an effective, low toxicity, non-pharmacologic treatment modality for hot flashes. ..
  3. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2006
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
  4. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2007
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
  5. A Novel Vitamin D Target in Human Prostate Cancer
    TOMASZ BEER; Fiscal Year: 2007
    ..New treatment targets are needed to develop new drugs to treat prostate cancer, the most commonly diagnosed cancer and the second-leading cancer killer in US men. ..
  6. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2009
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..